A multicentric open clinical trial was carried out by 8 practising specialists in dermatology or paediatrics in @entity1 with @entity4577 who were subjected to a systemic therapy with @entity17036 (= @entity68768 ). The @entity17036 presentation for adults and schoolchildren was tablets of 750 mg each, and sachets of 125 mg or 250 mg for @entity1 . The duration of treatment was 10 days. The parameters analyzed were bacteriological findings and the clinical course of disease. 71 (=74%) of the 96 @entity1 included in this study were considered as cured, 21 (=22%) as improved and 4 @entity1 (=4%) as unchanged. Bacterial identification was still positive in 10 cases after the termination of treatment. However, this did not preclude the assessments of "cured'' (3 cases) or "improved'' (7 cases). The tolerance of the preparation was considered as "very good'' or "good'' in 91 and as "poor'' in 5 @entity1 . The most common side effects were @entity390 and @entity294 . Exanthema was observed in 2 cases. None of these side effects, however, made a discontinuation of medication necessary. The era of rational and well-directed chemotherapy enables good therapeutic approach also to @entity4577 .

[ @entity17036 in XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'infants'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity68768 :: ('MESH:C100243', 'Chemical') :: ['Azidocillin'] @entity17036 :: ('MESH:C100209', 'Chemical') :: ['Syncillin'] @entity4577 :: ('MESH:D017192', 'Disease') :: ['bacterial skin diseases']
@entity4577 :: (MESH:D017192,Disease) :: ['bacterial skin diseases']
